TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07774403: A Phase II Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Sponsor: AstraZeneca · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 84 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT07774403 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07774403 Rescue Dossier →